Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
BeOne Medicines AG banner

BeOne Medicines AG
NASDAQ:ONC

Watchlist Manager
BeOne Medicines AG Logo
BeOne Medicines AG
NASDAQ:ONC
Watchlist
Price: 353.83 USD 2.11% Market Closed
Market Cap: $493.2B
Write Note Create Alert Ask AI

Wall St Price Targets

ONC Price Targets Summary
BeOne Medicines AG

Wall Street analysts forecast ONC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ONC is 519.75 USD with a low forecast of 433.76 USD and a high forecast of 670.06 USD.

ONC Lowest Forecast
Wall Street Target
$433.76
23% Upside
ONC Average Forecast
Wall Street Target
$519.75
47% Upside
ONC Highest Forecast
Wall Street Target
$670.06
89% Upside
Lowest Forecast
Price Target
433.76 USD
23% Upside
Average Forecast
Price Target
519.75 USD
47% Upside
Highest Forecast
Price Target
670.06 USD
89% Upside
BeOne Medicines AG Competitors:
Price Targets

Revenue
Forecast

53% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat
53% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat

Over the last 6 years, the compound annual growth rate for Revenue has been 53%. The projected CAGR for the next 8 years is 11%.

What are analyst estimates?

Gross Profit
Forecast

54% / Year
Past Growth
10% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
54% / Year
Past Growth
10% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 6 years, the compound annual growth rate for Gross Profit has been 54%. The projected CAGR for the next 6 years is 10%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
33% / Year
Estimated Growth
Estimates Accuracy
10%
Average Beat
N/A
Past Growth
33% / Year
Estimated Growth
Estimates Accuracy
10%
Average Beat

The compound annual growth rate for Operating Income over the next 8 years is 33%.

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
73% / Year
Estimated Growth
Estimates Accuracy
13%
Average Beat
N/A
Past Growth
73% / Year
Estimated Growth
Estimates Accuracy
13%
Average Beat

The compound annual growth rate for Pre-Tax Income over the next 3 years is 73%.

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
45% / Year
Estimated Growth
Estimates Accuracy
17%
Average Beat
N/A
Past Growth
45% / Year
Estimated Growth
Estimates Accuracy
17%
Average Beat

The compound annual growth rate for Net Income over the next 8 years is 45%.

What are analyst estimates?

Continue ONC Research

Summary
ONC intrinsic value, competitors valuation, and company profile.
DCF Valuation
ONC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ONC stock valuation using valuation multiples.
Wall St Estimates
ONC price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ONC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other BeOne Medicines AG listings:
HKEX • HKD
6160
 SSE • CNY
688235
 SWB • EUR
49BA
 OTC • USD
BEIGF
 F • EUR
49BA
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is ONC's stock price target?
Price Target
519.75 USD

According to Wall Street analysts, the average 1-year price target for ONC is 519.75 USD with a low forecast of 433.76 USD and a high forecast of 670.06 USD.

What is the Revenue forecast for BeOne Medicines AG?
Projected CAGR
11%

Over the last 6 years, the compound annual growth rate for Revenue has been 53%. The projected CAGR for the next 8 years is 11%.

What is the Gross Profit forecast for BeOne Medicines AG?
Projected CAGR
10%

Over the last 6 years, the compound annual growth rate for Gross Profit has been 54%. The projected CAGR for the next 6 years is 10%.

What is the Operating Income forecast for BeOne Medicines AG?
Projected CAGR
33%

The compound annual growth rate for Operating Income over the next 8 years is 33%.

What is the Pre-Tax Income forecast for BeOne Medicines AG?
Projected CAGR
73%

The compound annual growth rate for Pre-Tax Income over the next 3 years is 73%.

What is the Net Income forecast for BeOne Medicines AG?
Projected CAGR
45%

The compound annual growth rate for Net Income over the next 8 years is 45%.

Back to Top
ALPHA SPREAD
Follow us
Join 357,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.